Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Modalis TherapeuticsTSE:4883 +3.03%20 Current Ratio is 21.46 as of Dec. 2025, which is 27% below its 10-year median of 29.44. GuruFocus rates TSE:4883 with a GF Score™ of 20/100. The stock has 2 warning signs investors should review. Among 1,000 Drug Manufacturers companies, Modalis Therapeutics ranks better than 98.5% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Modalis Therapeutics's current ratio for the quarter that ended in Dec. 2025 was 21.46.
Modalis Therapeutics has a current ratio of 21.46. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Modalis Therapeutics's Current Ratio or its related term are showing as below:
TSE:4883'
s Current Ratio Range Over the Past 10 Years
Min: 9.88 Med: 29.44 Max: 93.51
Current: 25.02
During the past 8 years, Modalis Therapeutics's highest Current Ratio was 93.51. The lowest was 9.88. And the median was 29.44.
TSE:4883's Current Ratio is ranked better than 98.5% of 1000
companies
in the Drug Manufacturers industry
Industry Median: 2
vs TSE:4883: 25.02
Modalis Therapeutics (TSE:4883) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Modalis Therapeutics Current Ratio Related Terms
Modalis Therapeutics Current Ratio Historical Data
* Premium members only.
The historical data trend for Modalis Therapeutics's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Modalis Therapeutics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Modalis Therapeutics Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Modalis Therapeutics's Current Ratio distribution charts can be found below:
* The bar in red indicates where Modalis Therapeutics's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Modalis Therapeutics (TSE:4883) has a Current Ratio of 21.46 as of Dec. 2025. This is 27% below median its historical median of 29.44. Over the past decade, Modalis Therapeutics' Current Ratio has ranged from 9.88 to 93.51. According to the industry distribution chart, Modalis Therapeutics ranks #15 out of 1000 companies in the Drug Manufacturers industry, placing it in the top 1.5%.
Is Modalis Therapeutics' Current Ratio too high?
Modalis Therapeutics' current Current Ratio of 21.46 is 27% below median its 10-year median of 29.44. Over the past 10 years, this metric has ranged from a low of 9.88 to a high of 93.51. The Drug Manufacturers industry median Current Ratio is 2.00. Modalis Therapeutics' value of 21.46 is 973% above this industry median. Based on the distribution chart, Modalis Therapeutics ranks #15 out of 1000 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Modalis Therapeutics has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Modalis Therapeutics' Current Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Modalis Therapeutics ranks #15 out of 1000 companies for Current Ratio. This places Modalis Therapeutics in the top 2% of its industry — outperforming the majority of peers. The industry median Current Ratio is 2.00. Modalis Therapeutics' value of 21.46 is 973% above this benchmark. Historically, Modalis Therapeutics' own Current Ratio has ranged from 9.88 to 93.51 over the past decade. While the company's 10-year median is 29.44 vs. the industry median of 2.00, Modalis Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 1,000 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Modalis Therapeutics's current Current Ratio of 21.46 is 973% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Modalis Therapeutics's current Current Ratio is 21.46, which is 27% below median its own 10-year median of 29.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Modalis Therapeutics stock overvalued right now?
Modalis Therapeutics (TSE:4883) has a current Current Ratio of 21.46. The current Current Ratio is 21.46, which is 27% below median its 10-year median of 29.44 and 973% above the Drug Manufacturers industry median of 2.00. Modalis Therapeutics' overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Modalis Therapeutics (TSE:4883), the current Current Ratio is 21.46 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Modalis Therapeutics Corp is a drug development company. It is engaged in research and development of Gene Therapy using core platform technology, non-editing CRISPR technology (CRISPR-GNDM). The company's products in the pipeline are MDL-201, MDL-202, MDL-204, MDL-205, MDL-206, MDL-101, and MDL-102.
20GF Score
Get the complete analysis for TSE:4883
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4883 has been successfully added to your 
